Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Supernus Pharmaceuticals ( (SUPN) ) has provided an announcement.
On June 13, 2025, Supernus Pharmaceuticals announced a definitive agreement to acquire Sage Therapeutics through a tender offer valued at approximately $795 million. This acquisition is expected to enhance Supernus’ neuropsychiatry product portfolio with the addition of ZURZUVAE, an FDA-approved treatment for postpartum depression, and is anticipated to be significantly accretive by 2026, with potential cost synergies of up to $200 million annually.
The most recent analyst rating on (SUPN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Supernus Pharmaceuticals stock, see the SUPN Stock Forecast page.
Spark’s Take on SUPN Stock
According to Spark, TipRanks’ AI Analyst, SUPN is a Neutral.
Supernus Pharmaceuticals demonstrates strong financial health and promising growth in core products, contributing positively to its score. However, high valuation, mixed technical indicators, and recent patent challenges pose risks that moderate the overall outlook.
To see Spark’s full report on SUPN stock, click here.
More about Supernus Pharmaceuticals
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, with a diverse portfolio that includes treatments for ADHD, Parkinson’s disease, epilepsy, migraine, and other CNS disorders.
Average Trading Volume: 511,684
Technical Sentiment Signal: Hold
Current Market Cap: $1.79B
See more insights into SUPN stock on TipRanks’ Stock Analysis page.